sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
human
result
acut
respiratori
distress
syndrom
ard
patient
mortal
passiv
antibodi
therapi
success
use
treat
patient
infect
sarscov
confer
protect
lethal
challeng
experiment
anim
reemerg
sar
human
remain
credibl
health
threat
anim
reservoir
effect
treatment
sar
howev
sinc
viru
titer
peak
day
postinfect
postexposur
treatment
effect
broad
spectrum
viral
variant
remain
viabl
option
mani
report
hmab
sarscov
fail
neutral
clinic
isol
therefor
need
clinic
usabl
therapi
sarscov
infect
spike
glycoprotein
play
essenti
role
receptor
bind
membran
fusion
critic
viru
entri
contain
epitop
elicit
neutral
ab
sarscov
protein
consist
two
function
domain
amino
acid
amino
acid
receptor
bind
domain
rbd
amino
acid
contain
within
domain
requir
bind
receptor
cell
surfac
thought
contain
major
neutral
epitop
cocrystal
rbd
human
identifi
receptor
bind
motif
rbm
amino
acid
direct
contact
domain
contain
fusion
peptid
follow
two
conserv
heptad
repeat
ie
upon
cleavag
cathepsinl
associ
form
fusion
core
facilit
fusion
cell
membran
requir
viru
entri
synthet
peptid
well
specif
antibodi
shown
block
sarscov
infect
rbd
show
high
rate
mutat
allow
viru
escap
neutral
ab
without
lose
abil
infect
cell
contrast
domain
highli
conserv
among
differ
clinic
isol
sarscov
thu
rais
possibl
ab
region
may
confer
better
protect
broad
spectrum
clinic
isol
previous
use
xenomous
mous
immunoglobulin
gene
replac
human
immunoglobulin
gene
immun
sarscov
urbani
strain
protein
ectodomain
produc
panel
neutral
hmab
found
bound
region
protein
found
hmab
bound
rbd
neutral
viru
block
viru
bind
receptor
one
hmab
neutral
viru
inhibit
postbind
event
studi
describ
neutral
hmab
specif
bind
region
found
hmab
unlik
specif
hmab
better
abl
neutral
broader
rang
surrog
clinic
isol
express
plasmid
encod
fragment
sarscov
urbani
spike
protein
n
termin
signal
sequenc
ctermin
human
igg
fc
use
templat
site
direct
mutagenesi
pcr
use
quikchang
lightn
sitedirect
mutagenesi
kit
stratagen
gener
gzc
mutant
procedur
primer
use
gener
full
length
protein
mutant
construct
use
code
full
length
sarscov
protein
ctermin
tag
deriv
human
rhodopsin
protein
templat
encod
full
length
protein
sarscov
use
templat
pcr
reaction
amplifi
sectodomain
residu
residu
residu
residu
domain
forward
primer
design
nhei
site
revers
primer
design
bamhi
site
pcr
product
clone
frame
cterminu
igg
tag
mammalian
express
vector
plasmid
code
protein
well
protein
truncat
sectodomain
domain
use
transfect
cell
calcium
phosphat
transfect
method
protein
purifi
use
protein
agaros
bead
describ
previous
purifi
protein
concentr
centricon
filter
millipor
bedford
detect
coomassi
blue
stain
biorad
hercul
ca
follow
separ
sdspage
gel
express
confirm
western
blot
use
polyclon
goat
antihuman
igg
fc
hrp
antibodi
promega
hybridoma
neutral
non
bind
hmab
clone
limit
dilut
clone
cultur
dmem
medium
supplement
fetal
clone
hyclon
laboratori
logan
utah
produc
larg
quantiti
hmab
hmab
purifi
use
proteina
agaros
bead
thirti
nine
hmab
success
purifi
ab
product
confirm
sdspage
follow
coomassi
blue
stain
antibodi
concentr
measur
nm
use
uvvis
spectrophotomet
thermoscientif
hmab
dilut
final
concentr
medisorp
elisa
plate
nunc
roskild
denmark
coat
ngwell
urbani
protein
well
mutant
protein
gzc
overnight
bind
hmab
test
elisa
describ
previous
use
antihuman
hrp
mous
monoclon
antibodi
secondari
antibodi
southernbiotech
birmingham
al
procedur
follow
test
bind
non
neutral
hmab
protein
ectodomain
domain
protein
pseudotyp
virus
gener
cotransfect
produc
cell
grown
dmem
fb
phivgfpluc
express
vector
pgagpol
hiv
vector
phivrev
phivtat
along
code
sarscov
protein
use
calcium
phosphat
transfect
accord
previous
describ
protocol
product
hiv
vector
transfect
cell
media
chang
follow
morn
supernat
collect
hr
later
pool
pseudotyp
virus
concentr
sucros
cushion
rpm
use
beckman
ultracentrifug
incorpor
protein
viru
particl
confirm
western
blot
use
antirhodopsin
mous
monoclon
antibodi
santa
cruz
biotechnolog
santa
cruz
ca
viru
content
confirm
mous
monoclon
antibodi
santa
cruz
biotechnolog
santa
cruz
ca
entri
inhibit
perform
preincub
urbani
mutant
pseudovirus
equival
nanogram
ag
quantifi
elisa
kit
express
biotech
intern
md
purifi
mab
individu
combin
hr
pseudovirusmab
mixtur
pseudoviru
alon
ad
target
stabl
cell
line
plate
densiti
cellswel
well
plate
incub
overnight
medium
replac
follow
morn
forti
eight
hour
later
cell
lyse
luciferas
express
determin
use
luciferas
assay
kit
promega
wi
accord
manufactur
instruct
rabbit
immun
serum
use
posit
control
entri
inhibit
percentag
entri
inhibit
calcul
use
follow
equat
antibodi
mediat
inhibit
differ
mutant
pseudovirus
normal
hivurbani
inhibit
sarscov
protein
consist
domain
rbd
contain
major
neutral
epitop
domain
consist
mainli
domain
fig
identifi
broadli
neutral
hmab
want
test
hmab
rel
larg
panel
variant
align
rbd
amino
acid
sequenc
avail
sarscov
late
clinic
isol
found
mutat
rbd
region
four
clinic
isol
rel
urbani
rbd
sequenc
fig
clinic
isol
identifi
rbd
mutat
name
gzc
genbank
access
number
respect
insert
identifi
mutat
within
rbd
site
direct
mutagenesi
urbani
sequenc
fuse
human
fc
tag
cterminu
urbani
mutat
protein
express
cell
purifi
analyz
sdspage
fig
follow
western
blot
fig
rel
bind
hmab
differ
protein
differ
concentr
antibodi
determin
bind
highest
concentr
use
shown
interestingli
protein
fail
react
hmab
od
compar
control
od
howev
hmab
show
bind
protein
rel
bind
urbani
protein
fig
protein
show
diminish
bind
hmab
bind
hmab
respect
fig
protein
show
minim
bind
hmab
bind
hmab
respect
fig
surprisingli
gzc
protein
show
increas
bind
hmab
fig
diminish
bind
mutant
confirm
minim
bind
hmab
even
well
coat
excess
amount
mutant
protein
ie
ng
rel
signific
bind
ng
protein
data
shown
valid
find
confirm
found
antisarscov
urbani
polyclon
serum
show
strong
reactiv
od
mutant
even
high
dilut
show
much
lower
bind
protein
rel
bind
protein
fig
enhanc
bind
protein
valid
found
littl
ng
gzc
protein
could
block
hmab
bind
protein
much
ng
urbani
protein
significantli
less
effici
block
hmab
bind
protein
fig
prepar
pseudovirus
express
protein
contain
rbd
sequenc
gzc
isol
serv
rbd
surrog
clinic
isol
protein
hiv
ag
incorpor
viral
particl
confirm
western
blot
fig
expect
surfac
glycoprotein
detect
pseudovirus
express
mutant
protein
enter
cell
stabli
express
equal
effici
compar
hiv
posit
control
fig
consist
bind
data
shown
entri
inhibit
pseudovirus
rang
except
hmab
show
inhibit
rel
seen
urbani
pseudoviru
correspond
antibodi
fig
contrast
antibodi
show
effici
inhibit
gzc
mutant
fig
hmab
show
signific
inhibit
vsvg
pseudotyp
viru
ensur
specif
hmab
data
shown
recombin
protein
ectodomain
domain
protein
express
cell
purifi
use
proteina
agaros
bead
fig
thirti
nine
bind
urbani
strain
sectodomain
bind
neutral
hmab
success
purifi
test
bind
differ
region
protein
includ
domain
neg
control
fulllength
sectodomain
posit
control
od
neg
control
control
od
consid
posit
twenti
two
hmab
bound
domain
nine
thirteen
bound
specif
region
respect
tabl
interestingli
seventeen
hmab
bound
sectodomain
fail
bind
region
domain
inhibit
differ
pseudovirus
entri
bind
hmab
rang
urbani
pseudoviru
inhibit
antibodi
concentr
tabl
contrast
sectodomain
bind
hmab
less
effect
show
entri
inhibit
rang
urbani
inhibit
except
hmab
show
neutral
viru
hmab
show
neutral
gzc
viru
tabl
collect
result
show
bind
hmab
effect
inhibit
entri
rbd
surrog
clinic
isol
hmab
inhibit
entri
vsvg
pseudotyp
viru
data
shown
next
test
combin
bind
ntermin
rbd
bind
bind
hmab
see
effect
inhibit
viral
entri
combin
hmab
effect
block
urbani
pseudoviru
entri
compar
individu
antibodi
p
valu
pattern
inhibit
seen
gzc
pseudovirus
p
valu
howev
hmab
combin
exhibit
similar
level
pseudoviru
block
seen
hmab
use
individu
maximum
inhibit
p
valu
note
combin
hmab
use
fig
result
indic
cocktail
hmab
target
differ
conserv
region
protein
like
effect
neutral
differ
sarscov
clinic
isol
individu
antibodi
specif
region
therapi
direct
toward
rna
virus
includ
sarscov
must
consid
quasispeci
natur
viral
popul
abil
viru
mutat
recombin
respons
host
select
pressur
chang
like
allow
sarscov
jump
intermedi
host
human
result
outbreak
therefor
therapi
sarscov
includ
passiv
immunotherapi
hmab
must
abl
neutral
wide
rang
clinic
isol
prevent
minim
gener
escap
mutant
studi
found
hmab
unabl
bind
recombin
mutant
fragment
ie
except
antibodi
show
decreas
bind
hmab
show
enhanc
bind
fragment
hmab
bind
epitop
resid
ntermin
rbd
neutral
sarscov
inhibit
postbind
step
viral
entri
hmab
continu
react
albeit
lesser
extent
surrog
clinic
isol
moreov
use
combin
hmab
hmab
show
synergist
effect
accordingli
earlier
well
current
result
highlight
import
hmab
neutral
sarscov
mutant
abil
compliment
hmab
identif
domain
specif
neutral
hmab
consist
previou
studi
show
bcell
respons
domain
patient
recov
sarscov
infect
studi
show
fragment
consist
amino
acid
induc
neutral
antibodi
therefor
find
thirteen
neutral
hmab
bind
domain
consist
previou
report
mous
specif
monoclon
antibodi
howev
ab
neither
human
origin
test
abil
neutral
differ
clinic
isol
find
nine
bind
neutral
hmab
novel
report
specif
neutral
antibodi
date
believ
hmab
target
epitop
within
domain
fail
bind
neutral
mutat
like
disrupt
conform
protein
result
loss
express
specif
epitop
contrast
domain
reactiv
hmab
abl
neutral
differ
rbd
surrog
isol
even
better
hmab
interestingli
analys
amino
acid
sequenc
protein
sarscov
clinic
isol
reveal
mutat
local
mutat
six
isol
ie
hszcb
mutat
gzc
isol
respect
isol
found
free
mutat
either
domain
previous
report
hmab
recogn
epitop
within
rbd
mutat
allow
virus
escap
neutral
without
loss
infect
often
found
substanti
current
studi
loss
neutral
differ
rbd
bind
antibodi
due
singl
mutat
protein
howev
region
contain
highli
conserv
neutral
epitop
mutat
like
lethal
due
critic
role
membran
fusion
requir
viru
entri
consequ
shown
result
specif
antibodi
neutral
broad
spectrum
sarscov
variant
limit
potenti
emerg
escap
mutant
especi
use
combin
base
result
obtain
use
combin
mab
hbv
rsv
previou
demonstr
highli
effici
neutral
sarscov
use
combin
hmab
reason
combin
hmab
target
differ
region
protein
would
like
confer
better
protect
differ
isol
combin
bind
hmab
either
result
increas
viru
neutral
mutant
gzc
compar
individu
hmab
failur
combin
increas
pseudoviru
inhibit
compar
inhibit
seen
either
alon
like
due
enhanc
bind
neutral
viru
hmab
use
individu
howev
combin
compris
hmab
show
signific
increas
viru
neutral
compar
individu
hmab
pair
result
suggest
use
cocktail
consist
hmab
bind
differ
conserv
region
protein
may
desir
therapeut
use
sarscov
infect
specul
support
earlier
studi
shown
far
difficult
select
viral
variant
presenc
either
polyclon
neutral
antibodi
cocktail
monoclon
neutral
antibodi
although
other
demonstr
util
cocktail
consist
mab
similar
mode
action
present
studi
show
util
cocktail
hmab
differ
specif
like
differ
mechan
action
neutral
broad
spectrum
sarscov
clinic
isol
sarscov
protein
class
fusion
protein
contain
region
highli
conserv
presenc
similar
structur
mani
class
viral
fusion
protein
point
common
fusion
mechan
use
differ
virus
therefor
monoclon
antibodi
conserv
region
might
constitut
effect
passiv
therapi
find
relev
design
highli
effect
passiv
therapi
sarscov
implic
develop
passiv
therapi
viral
infect
includ
influenza
hiv
